NEW YORK, May 20, 2002 (PRIMEZONE) -- StockDiagnostics.com announces that it has suspended its OPS Ratings(SM) on the following companies due to a diagnosis of The EPS Syndrome. OPS Ratings on over 7,500 companies can be found at: http://www.stockdiagnostics.com
OPS Ratings Suspensions: Concord EFS, Inc. (Nasdaq:CEFT) Current OPS Rating: "Suspended" (Previous OPS Rating: "1") Q1-2002 OPS -$.35 vs. Q1-2001 OPS $.14 Natco Group, Inc. (NYSE:NTG) Current OPS Rating: "Suspended" (Previous OPS Rating: "2") Q1-2002 OPS -$.43 vs. Q1-2001 OPS $.76 Taser International, Inc. (Nasdaq:TASR) Current OPS Rating: "Suspended" (Previous OPS Rating: "6") Q1-2002 OPS -$.20 vs. Q1-2001 OPS $.15
How are OPS Ratings determined?
"OPS Ratings" were discovered from StockDiagnostics.com's in-depth research on Operational Cash Flow. These studies revealed that a company's OPS(SM) (Operational-cashflow Per Share) logically falls into a mathematical sequence that ranks it into one of eight distinctive risk categories. Ratings are scaled 1 through 8, with number one (1), being the highest rating and number eight (8), the lowest. A "Rating Suspended" status is given for all companies diagnosed with "The EPS Syndrome" during the most recent four quarters.
For more information on OPS Ratings go to; http://www.stockdiagnostics.com/member/ops_rating.htm
For information on The EPS Syndrome, go to; http://www.stockdiagnostics.com/member/eps_syndrome.htm
About StockDiagnostic.com
StockDiagnostics.com has designed and built a proprietary data refinery that automates the process of collecting, sorting and organizing large amounts of securities pricing and financial data into comparative financial ratios. These ratios are used to identify Financial Statement and securities pricing variances or anomalies and to monitor changes in the performance of public companies.
For more information on StockDiagnostics.com go to; http://www.stockdiagnostics.com/member/help.htm#a1
Disclaimer:
The information provided by StockDiagnostics.com does not constitute a recommendation by StockDiagnostics.com to buy, sell or hold any security or to follow any particular trading or investment strategy. Also, the information provided should not be construed as, an offer, or a solicitation of an offer, to buy or sell securities. An Investor's best course of action must be based upon individual circumstances. StockDiagnostics.com shall not be liable for any damages or costs of any type arising out of or in any way connected with your use of our services.